XLON
N4P
Market cap5mUSD
May 15, Last price
0.48GBP
1D
0.00%
1Q
-9.52%
IPO
-99.32%
Name
N4 Pharma PLC
Chart & Performance
P/E
—
P/S
207,849.52
EPS
—
Div Yield, %
—
Shrs. gr., 5y
21.61%
Rev. gr., 5y
-60.78%
Revenues
2k
Net income
-1m
L+23.32%
CFO
-1m
L+45.98%
Dividend
May 19, 19970.005625 GBP/sh
Earnings
Sep 22, 2025
Profile
N4 Pharma Plc, a specialist pharmaceutical company, develops novel silica nanoparticle delivery system for pharmaceutical and biotechnology companies in the United Kingdom. It develops Nuvec, a non-viral adjuvant delivery system for vaccines and cancer treatments. N4 Pharma Plc was incorporated in 1979 and is based in London, the United Kingdom.
Valuation
Title GBP in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|
| 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | 2015‑12 | |
| Income | |||||||||
Revenues | 2 | ||||||||
Cost of revenue | 1,337 | 1,193 | |||||||
Unusual Expense (Income) | |||||||||
NOPBT | (1,335) | (1,193) | |||||||
NOPBT Margin | |||||||||
Operating Taxes | (148) | (164) | |||||||
Tax Rate | |||||||||
NOPAT | (1,188) | (1,029) | |||||||
Net income | (1,269) 23.32% | (1,029) -33.35% | |||||||
Dividends | |||||||||
Dividend yield | |||||||||
Proceeds from repurchase of equity | 350 | 1,054 | |||||||
BB yield | -16.95% | -30.56% | |||||||
| Debt | |||||||||
Debt current | |||||||||
Long-term debt | |||||||||
Deferred revenue | |||||||||
Other long-term liabilities | 36 | ||||||||
Net debt | (1,027) | (1,920) | |||||||
| Cash flow | |||||||||
Cash from operating activities | (1,209) | (828) | |||||||
CAPEX | |||||||||
Cash from investing activities | 781 | ||||||||
Cash from financing activities | 316 | 964 | |||||||
FCF | (1,124) | (852) | |||||||
| Balance | |||||||||
Cash | 1,027 | 1,920 | |||||||
Long term investments | |||||||||
Excess cash | 1,027 | 1,920 | |||||||
Stockholders' equity | 178 | (7,022) | |||||||
Invested Capital | 1,016 | 9,110 | |||||||
ROIC | |||||||||
ROCE | |||||||||
| EV | |||||||||
Common stock shares outstanding | 242,890 | 186,423 | |||||||
Price | 0.01 -54.05% | 0.02 -58.43% | |||||||
Market cap | 2,065 -40.14% | 3,449 -57.20% | |||||||
EV | 1,103 | 1,529 | |||||||
EBITDA | (1,335) | (1,193) | |||||||
EV/EBITDA | |||||||||
Interest | 1 | ||||||||
Interest/NOPBT | |||||||||